IPLA
BMRN icon

Ice Pond Lane Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ice Pond Lane Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-40,000
Closed -$3.51M – 16
2017
Q1 		$3.51M Hold
40,000
– – 0.92% 15
2016
Q4 		$3.31M Buy
+40,000
New +$3.44M 0.5% 17

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ice Pond Lane Advisers's BMRN Position: Q2 2017 in Review

Ice Pond Lane Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2017, closing a stake of 40,000 shares — an estimated $3.51M sold.

Ice Pond Lane Advisers first reported a position in BMRN in Q4 2016 and held it in 2 quarters. The position peaked at $3.51M in Q1 2017. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

  • Ice Pond Lane Advisers reported no remaining BioMarin Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Ice Pond Lane Advisers sold 40,000 BioMarin Pharmaceuticals shares in Q2 2017, an estimated $3.51M.
  • Ice Pond Lane Advisers first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Ice Pond Lane Advisers's BioMarin Pharmaceuticals position peaked at $3.51M in Q1 2017.
  • 426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on Ice Pond Lane Advisers's 13F filing for Q2 2017, filed 14 Aug 2017.